Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to...
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless...
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular...
Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement...
Into the Dark Into the Dark Campaign ImageEmphasizes challenges faced by patients and clinicians within the first 30 days after...
JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)...
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products...
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
Management to provide an update on its regulatory and partnering strategy for the United States and EuropeCHARLOTTESVILLE, Va., March 02,...
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern TimeYAVNE, Israel, March 02, 2023 (GLOBE NEWSWIRE)...
REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on...
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular...
AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease...
VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Jari Karlson Orion Corporation...
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Olli Huotari Orion Corporation...
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Satu Ahomäki Orion Corporation...
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Juhani Kankaanpää Orion Corporation...
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Virve Laitinen Orion Corporation...
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Niclas Lindstedt Orion Corporation...